Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
about
Clostridium difficile phages: still difficult?Fidaxomicin: A novel agent for the treatment of Clostridium difficile infectionDisruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic ResistanceEfficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-AnalysisClostridium difficile Infection in Children: Current State and Unanswered QuestionsTrends in Clostridium difficile Disease: Epidemiology and InterventionClostridium difficile Infection and Fecal Microbiota Transplant.[Clostridium difficile infections in geriatric patients].Clostridium difficile infection: New insights into therapeutic options.Clinical pearls in infectious diseases.Exploiting CRISPR-Cas to manipulate Enterococcus faecalis populations.Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazoleProgress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonizationFidaxomicin therapy in critically ill patients with Clostridium difficile infection.A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.A review of the economics of treating Clostridium difficile infection.Clostridium difficile infection: current, forgotten and emerging treatment options.Mathematical model of the impact of a nonantibiotic treatment for Clostridium difficile on the endemic prevalence of vancomycin-resistant enterococci in a hospital setting.A novel agent effective against Clostridium difficile infection.In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.Decreased microbial diversity and Lactobacillus group in the intestine of geriatric giant pandas (Ailuropoda melanoleuca).Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycinCharacterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in TaiwanPharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challengeEffect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.Easily modified factors contribute to delays in diagnosis of Clostridium difficile infection: a cohort study and interventionEmerging therapies for Clostridium difficile infection - focus on fidaxomicin.Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.Effects of treatment with antimicrobial agents on the human colonic microfloraClostridium difficile infection in the intensive care unit.Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.Alternative therapies for Clostridium difficile infections.Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study.Antimicrobial resistance in internal medicine wards.
P2860
Q21131097-A3A23C30-A98B-4F68-8703-77EB82F9B618Q26770175-8B46171A-112E-4201-959C-7895046B67C5Q26771995-3F9B737E-39DF-4186-8BD9-41A72C647EFDQ26786662-81777BE0-0231-4498-A30C-01058E1F20FBQ27016320-DAF5D792-036C-49B0-B1DC-F026E0C9EACFQ28655729-541DB866-182B-4FC7-9C7B-822063301615Q30240065-7162768A-46DF-484A-B71D-C59CE178DBA6Q30244040-BEC8CDC8-19BC-47E1-8AC2-B58B867D40B2Q30252154-EBD0D071-C71C-4944-881A-436E8325304BQ33620412-6AB5B633-6A73-4C14-99C1-34D818A8EFF6Q33853796-F9A08702-B38C-479A-8B17-B6605E5A105AQ35009326-CCB95EC9-90CE-4D34-AD18-1BC712959A01Q35044119-01B02654-497D-41AD-BC40-7158E4559157Q35072513-6DB12F98-EF3E-486A-8325-06A1F0BAD5CAQ35076869-451666DE-F3EF-4B0B-93E4-720FDEFA71B8Q35146382-5FF42C16-9333-49E2-95BB-B484A49C93D1Q35164905-3FA2DFC2-CAE7-48A3-8D60-D547D620BD27Q35372397-95C6697C-09E8-4975-A933-444040ED5CAAQ35691700-EF8C82F8-19F1-45DB-B455-5F5EF7E88267Q35806246-03EBA65D-A5D4-48A4-83EF-DC9313B9A921Q35806432-294D3562-FB54-459B-A1A5-E7357A3FF7EFQ35898582-D18F7BCF-2FC7-4BAC-9A63-FD2D75F42B52Q35977955-5CEF7C73-E062-4362-9CD5-3A102AB98C11Q36071504-6535BD5F-C513-41EF-A2ED-2E1AD7F31426Q36071520-F379EC10-905B-4195-A60A-886D844D8DCAQ36071524-44AED53F-2297-430C-A1E0-44F6553695EAQ36086377-BBB16A48-C867-4E80-B8D4-2AD0AC532F14Q36324415-00535877-1AD0-466F-A853-917104F8ABE7Q36889259-C88CB0F5-8BA6-411B-B3EE-D1E81DBCB243Q36933317-C521EF05-E989-4100-B94E-860B89106613Q36971164-E45A3F6F-EC50-46DE-BD33-F1B029B2AB3DQ36984883-B6C0B0BC-4F84-4F6F-9EDF-89A2F06760E8Q37023290-68A47B60-3C9F-48DF-84B8-1BE213A25CFFQ37098178-1612B5D4-3088-42DF-83F6-D05DB06C1155Q37305032-48D1DECE-3D76-431E-83B7-51EDE0FED39CQ37588248-ED81EE21-7820-4C9A-AB38-C6DE5DB74B0DQ37813126-7C2406CF-883E-4C9E-A3A4-EDC778E4AEC0Q37933407-7664FBC9-31DE-49C4-8186-061621CD112FQ38049612-DFCAD2B7-FD21-4DF0-975B-217F1A2EDF62Q38052855-8A6DE514-26E5-4059-A6DE-BDDC3C9360C0
P2860
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Both oral metronidazole and or ...... m difficile-associated disease
@ast
Both oral metronidazole and or ...... m difficile-associated disease
@en
type
label
Both oral metronidazole and or ...... m difficile-associated disease
@ast
Both oral metronidazole and or ...... m difficile-associated disease
@en
prefLabel
Both oral metronidazole and or ...... m difficile-associated disease
@ast
Both oral metronidazole and or ...... m difficile-associated disease
@en
P2093
P2860
P356
P1476
Both oral metronidazole and or ...... m difficile-associated disease
@en
P2093
Ajay K Sethi
Michael J Pultz
Michelle M Riggs
Wafa N Al-Nassir
P2860
P304
P356
10.1128/AAC.00090-08
P407
P577
2008-04-28T00:00:00Z